Clinical applications of virosomes in cancer immunotherapy (Q36627236)

15 August 2017

1 reference

title

Clinical applications of virosomes in cancer immunotherapy (English)

1 reference

15 August 2017

1 reference

1

Michel Adamina

1 reference

15 August 2017

2

Ulrich Guller

1 reference

15 August 2017

Laura Bracci

3

1 reference

15 August 2017

Michael Heberer

series ordinal

4

1 reference

15 August 2017

Giulio C Spagnoli

series ordinal

5

1 reference

15 August 2017

Reto Schumacher

series ordinal

6

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 November 2006

1 reference

Expert Opinion on Biological Therapy

15 August 2017

1 reference

15 August 2017

6

1 reference

15 August 2017

11

1 reference

15 August 2017

1113-1121

1 reference

A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma

15 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1113

A listing of human tumor antigens recognized by T cells: March 2004 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1113

Cancer immunoediting: from immunosurveillance to tumor escape

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1113

CD28/B7 system of T cell costimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1113

Phase I/II clinical trial of a nonreplicative vaccinia virus expressing multiple HLA-A0201-restricted tumor-associated epitopes and costimulatory molecules in metastatic melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1113

Nonreplicating recombinant vaccinia virus expressing CD40 ligand enhances APC capacity to stimulate specific CD4+ and CD8+ T cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1113

Peptides naturally presented by MHC class I molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1113

Hydrolysis of the tumor-associated antigen epitope gp100(280-288) by membrane-associated and soluble enzymes expressed by immature and mature dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1113

Encapsulation into sterically stabilised liposomes enhances the immunogenicity of melanoma-associated Melan-A/MART-1 epitopes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1113

Clinical applications of recombinant virus-based cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1113

Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1113

Rapid induction of specific cytotoxic T lymphocytes against melanoma-associated antigens by a recombinant vaccinia virus vector expressing multiple immunodominant epitopes and costimulatory molecules in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1113

Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1113

Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1113

Induction of CD8+ T cells using heterologous prime-boost immunisation strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1113

Formation of virosomes from influenza subunits and liposomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1113

Liposomes to target the lymphatics by subcutaneous administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1113

Gene transfer mediated by fusion protein hemagglutinin reconstituted in cationic lipid vesicles

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1113

Delivery to cancer cells of antisense L-myc oligonucleotides incorporated in fusogenic, cationic-lipid-reconstituted influenza-virus envelopes (cationic virosomes).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1113

Novel approaches in the development of immunopotentiating reconstituted influenza virosomes as efficient antigen carrier systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1113

Influenza virosomes as an efficient system for adjuvanted vaccine delivery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1113

Immunostimulating reconstituted influenza virosomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1113

Optimal therapy for platinum-resistant recurrent ovarian cancer: doxorubicin, gemcitabine or topotecan?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1113

Polyethylene glycol-liposomal doxorubicin: a review of its use in the management of solid and haematological malignancies and AIDS-related Kaposi's sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1113

Liposomal amphotericin B: clinical experience and perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1113

Effect of substitution of hemagglutinin-neuraminidase with influenza hemagglutinin on Sendai virus F protein mediated membrane fusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1113

Reconstituted Sendai virus envelopes as biological carriers: dual role of F protein in binding and fusion with liver cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1113

Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1113

Immune response to human papillomavirus 16 L1E7 chimeric virus-like particles: induction of cytotoxic T cells and specific tumor protection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1113

Recombinant parvovirus-like particles as an antigen carrier: a novel nonreplicative exogenous antigen to elicit protective antiviral cytotoxic T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1113

Priming of class I-restricted cytotoxic T lymphocytes by vaccination with recombinant protein antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1113

Nonmethylated CG motifs packaged into virus-like particles induce protective cytotoxic T cell responses in the absence of systemic side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1113

Engineered liposomes and virosomes for delivery of macromolecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1113

Mimicking rubella virus particles by using recombinant envelope glycoproteins and liposomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1113

Preparation of virosomes coated with the vesicular stomatitis virus glycoprotein as efficient gene transfer vehicles for animal cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1113

Tat Peptide-Mediated Intracellular Delivery of Liposomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1113

Development of a Virosome Vaccine for Newcastle Disease Virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1113

Intercellular trafficking and protein delivery by a herpesvirus structural protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1113

Virosomes for antigen and DNA delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1113

Influenza virosomes enhance class I restricted CTL induction through CD4+ T cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1113

Virosomes as new carrier system for cancer vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1113

Virosome-mediated delivery of protein antigens in vivo: efficient induction of class I MHC-restricted cytotoxic T lymphocyte activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1113

Granulocyte-macrophage-colony-stimulating factor added to a multipeptide vaccine for resected Stage II melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1113

Mucosal antibody response induced with a nasal virosome-based influenza vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1113

Degradation of the tumor antigen epitope gp100(280-288) by fibroblast-associated enzymes abolishes specific immunorecognition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1113

10.1517/14712598.6.11.1113

21 January 2018

Identifiers

DOI

1 reference

15 August 2017

1 reference